Giulia Braccini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Giulia Braccini has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Elena Levantini
Institute of Biomedical Technologies, National Research Council (CNR) Pisa Italy
50 shared publications - Giorgia Maroni
CNR-Consiglio Nazionale delle Ricerche, Istituto di Tecnologie Biomediche (ITB-CNR), Area della Ricerca di Pisa, 56124 Pisa, Italy
50 shared publications - Art Branstrom
PTC Therapeutics, Inc
49 shared publications - Azhar Ali
Cancer Science Institute of Singapore, National University of Singapore, Singapore
49 shared publications - Barbara Storti
NEST, Scuola Normale Superiore and Istituto Nanoscienze-CNR, Piazza San Silvestro 12, 56127 Pisa, Italy
49 shared publications - Daniel Geoffrey Tenen
Harvard Stem Cell Institute, Harvard Medical School, Boston, USA
49 shared publications
Latest Publications
- Open Access
Deciphering the Role of Acetate in Metabolic Adaptation and Drug Resistance in Non-Small Cell Lung Cancer
Resistance to targeted therapies remains a major challenge in EGFR-mutant non-small cell lung cancer (NSCLC). Here, we describe a novel metabolic adaptation in osimertinib-resistant cells characterized by elevated acetate levels and activation of an unconventional pyruvate/acetaldehyde/acetate (PAA) shunt. Integrated transcriptomic, exometabolomic, and functional analyses reveal suppression of canonical metabolic pathways and upregulation of ALDH2 and ALDH7A1, which mediate the NADP+ dependent oxidation of acetaldehyde to acetate, generating NADPH. This shift supports reducing power essential for biosynthesis and redox balance under conditions of oxidative pentose phosphate inhibition. These metabolic changes promote endurance in resistant cells and rewire the interplay between glycolysis, the pentose phosphate pathway, and the tricarboxylic acid cycle, offering a de novo bypass for anaplerosis and bioenergetics. Systematic metabolite profiling revealed distinct transcriptomic and metabolic signatures distinguishing resistant from parental cells. Together, these findings depict a unique, resistance-driven adaptive metabolic shift, and uncover potential therapeutic vulnerabilities in osimertinib-resistant NSCLC.
Open AccessDeciphering the Role of Acetate in Metabolic Adaptation and Drug Resistance in Non-Small Cell Lung Cancer
Resistance to targeted therapies remains a major challenge in EGFR-mutant non-small cell lung cancer (NSCLC). Here, we describe a novel metabolic adaptation in osimertinib-resistant cells characterized by elevated acetate levels and activation of an unconventional pyruvate/acetaldehyde/acetate (PAA) shunt. Integrated transcriptomic, exometabolomic, and functional analyses reveal suppression of canonical metabolic pathways and upregulation of ALDH2 and ALDH7A1, which mediate the NADP+ dependent oxidation of acetaldehyde to acetate, generating NADPH. This shift supports reducing power essential for biosynthesis and redox balance under conditions of oxidative pentose phosphate inhibition. These metabolic changes promote endurance in resistant cells and rewire the interplay between glycolysis, the pentose phosphate pathway, and the tricarboxylic acid cycle, offering a de novo bypass for anaplerosis and bioenergetics. Systematic metabolite profiling revealed distinct transcriptomic and metabolic signatures distinguishing resistant from parental cells. Together, these findings depict a unique, resistance-driven adaptive metabolic shift, and uncover potential therapeutic vulnerabilities in osimertinib-resistant NSCLC.
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 2. Size of each identified transcriptional cluster as percentage of all profiled cells.
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 2. Size of each identified transcriptional cluster as percentage of all profiled cells.
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
FIGURE 2 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
ScRNA-seq of healthy and tumor-bearing lungs highlights presence of pulmonary milieu clusters. A, t-SNE plot of the 41 clusters identified in healthy lungs (n = 3, left), and Vehicle- (n = 10, middle), or Unesbulin-treated tumors (n = 3, right), at 30 days. Each point represents one cell. Each color represents a defined transcriptional cluster as shown in the corresponding legends. B, t-SNE plot in which transcriptional clusters have been annotated as epithelial, immune, endothelial, or fibroblast subpopulations. C, Cluster distribution superimposed to clusters annotation within epithelial, immune, endothelial cells, and fibroblasts in healthy lungs (left), and Vehicle- (middle), or Unesbulin-treated tumors (right).
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 2 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
ScRNA-seq of healthy and tumor-bearing lungs highlights presence of pulmonary milieu clusters. A, t-SNE plot of the 41 clusters identified in healthy lungs (n = 3, left), and Vehicle- (n = 10, middle), or Unesbulin-treated tumors (n = 3, right), at 30 days. Each point represents one cell. Each color represents a defined transcriptional cluster as shown in the corresponding legends. B, t-SNE plot in which transcriptional clusters have been annotated as epithelial, immune, endothelial, or fibroblast subpopulations. C, Cluster distribution superimposed to clusters annotation within epithelial, immune, endothelial cells, and fibroblasts in healthy lungs (left), and Vehicle- (middle), or Unesbulin-treated tumors (right).
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
FIGURE 1 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
BMI-1 inhibition affects cell cycle progression and tumor growth. A, Western blot analyses of the human H1975 cell line treated for 24, 48, and 72 hours with DMSO Vehicle as control, and Unesbulin or PTC-028. Protein lysates were immunoblotted with an anti-BMI-1 or an anti-Tubulin antibody. Loading was assessed with an anti-β-actin antibody. Expected size is shown in kDa. The slower migrating hyperphosphorylated BMI-1 band is indicated by the arrowhead. B, Cell cycle analysis of the H1975 cell lines after treatment for 24 hours with DMSO (black), Unesbulin (light blue), or PTC-028 (dark blue). The bar charts represent the distribution of cells in G0, G1, and G2–M phases. P values are indicated. Error bars represent SD. Percentages of cells in each cell cycle phase are indicated. C, H1975 xenografts tumor volumes at treatment termination (Vehicle n = 15, black; Unesbulin n = 17, light blue; PTC208 n = 8, dark blue) normalized to the tumor volume measured at the beginning of treatment. The difference in tumor size at day 21 was statistically significant (P values are indicated). D, The graph shows percentage of change in transgenic mice tumor volume measured by MRI at the indicated timepoints, between Unesbulin (n = 8, light blue) and Vehicle-treated (n = 6, black) groups. Error bars represent SD. P value is indicated. E, Confocal microscopy fluorescence nuclear imaging of DNA and H2AK119ub in tumor tissues collected at the end of treatment. Top panels show a representative image of DMSO-treated tumor; bottom panels show a tumor treated with Unesbulin. Left panels show DNA staining by Hoechst 33342 (blue acquisition channel). Right panels show H2AK119ub staining by immunofluorescence (scale bar, 10 µm).
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 1 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
BMI-1 inhibition affects cell cycle progression and tumor growth. A, Western blot analyses of the human H1975 cell line treated for 24, 48, and 72 hours with DMSO Vehicle as control, and Unesbulin or PTC-028. Protein lysates were immunoblotted with an anti-BMI-1 or an anti-Tubulin antibody. Loading was assessed with an anti-β-actin antibody. Expected size is shown in kDa. The slower migrating hyperphosphorylated BMI-1 band is indicated by the arrowhead. B, Cell cycle analysis of the H1975 cell lines after treatment for 24 hours with DMSO (black), Unesbulin (light blue), or PTC-028 (dark blue). The bar charts represent the distribution of cells in G0, G1, and G2–M phases. P values are indicated. Error bars represent SD. Percentages of cells in each cell cycle phase are indicated. C, H1975 xenografts tumor volumes at treatment termination (Vehicle n = 15, black; Unesbulin n = 17, light blue; PTC208 n = 8, dark blue) normalized to the tumor volume measured at the beginning of treatment. The difference in tumor size at day 21 was statistically significant (P values are indicated). D, The graph shows percentage of change in transgenic mice tumor volume measured by MRI at the indicated timepoints, between Unesbulin (n = 8, light blue) and Vehicle-treated (n = 6, black) groups. Error bars represent SD. P value is indicated. E, Confocal microscopy fluorescence nuclear imaging of DNA and H2AK119ub in tumor tissues collected at the end of treatment. Top panels show a representative image of DMSO-treated tumor; bottom panels show a tumor treated with Unesbulin. Left panels show DNA staining by Hoechst 33342 (blue acquisition channel). Right panels show H2AK119ub staining by immunofluorescence (scale bar, 10 µm).
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 10. Size of each identified transcriptional cluster as percentage of all profiled cells.
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 10. Size of each identified transcriptional cluster as percentage of all profiled cells.
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 6. Size of each identified transcriptional cluster as percentage of all profiled cells.
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 6. Size of each identified transcriptional cluster as percentage of all profiled cells.
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 14 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 14. Size of each identified transcriptional cluster as percentage of all profiled fibroblasts.
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 14 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 14. Size of each identified transcriptional cluster as percentage of all profiled fibroblasts.
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 12 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 12. Size of each identified transcriptional cluster as percentage of all profiled endothelial cells.
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 12 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 12. Size of each identified transcriptional cluster as percentage of all profiled endothelial cells.
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 1. Size of each identified transcriptional cluster as percentage of all profiled cells.
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 1. Size of each identified transcriptional cluster as percentage of all profiled cells.
- Open Access
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 8 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 8. Size of each identified cell type as a percentage of all profiled cells.
- 10 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 8 from Tumor Microenvironment Landscapes Supporting EGFR-mutant NSCLC Are Modulated at the Single-cell Interaction Level by Unesbulin Treatment
Supplementary Table 8. Size of each identified cell type as a percentage of all profiled cells.